BioXcel Therapeutics (BTAI) Return on Capital Employed Growth (3y) (2021 - 2026)
BioXcel Therapeutics (BTAI) Return on Capital Employed Growth (3y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 39.72 Bn | 35.98 Bn | 1.97 Bn | 1,301.00 |
| 2 | Zoetis | 34.61 Bn | 32.67 Bn | 1.62 Bn | 353.00 |
| 3 | United Therapeutics | 24.07 Bn | 21.91 Bn | 648.10 Mn | 480.00 |
| 4 | Aurora Cannabis | 16.98 Bn | 16.91 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.64 Bn | 15.32 Bn | 800.70 Mn | 1,342.00 |
| 6 | Elanco Animal Health | 12.19 Bn | 11.76 Bn | 785.00 Mn | 2,112.00 |
| 7 | Alkermes | 7.37 Bn | 6.86 Bn | -116.06 Mn | 626.00 |
| 8 | Hims & Hers Health | 6.62 Bn | 5.87 Bn | 396.79 Mn | 1,809.00 |
| 9 | Lantheus Holdings | 6.47 Bn | 5.97 Bn | 230.92 Mn | 1,788.00 |
| 10 | BioXcel Therapeutics | 25.46 Mn | 25.46 Mn | -77,000.00 | 43,509.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 43,509.00 |
| Dec 31, 2025 | 63,919.00 |
| Sep 30, 2025 | 207,555.00 |
| Jun 30, 2025 | 437,439.00 |
| Mar 31, 2025 | -35,852.00 |
| Dec 31, 2024 | -26,874.00 |
| Sep 30, 2024 | -20,273.00 |
| Jun 30, 2024 | -19,157.00 |
| Mar 31, 2024 | -26,373.00 |
| Dec 31, 2023 | -24,939.00 |
| Sep 30, 2023 | -20,292.00 |
| Jun 30, 2023 | -6,886.00 |
| Mar 31, 2023 | -2,491.00 |
| Dec 31, 2022 | 2,345.00 |
| Sep 30, 2022 | 4,603.00 |
| Jun 30, 2022 | 3,966.00 |
| Mar 31, 2022 | 1,220.00 |
| Dec 31, 2021 | 288.00 |
| Sep 30, 2021 | -776.00 |
| Jun 30, 2021 | -2,279.00 |